Dayvigo and Trazodone Interaction: What Clinicians and Patients Need to Know

Why This Combination Appears So Frequently

Insomnia and depression co-occur in roughly 40% of adults with major depressive disorder, according to data from the National Comorbidity Survey Replication. Trazodone is prescribed off-label for insomnia at doses of 25 to 100 mg in tens of millions of patients annually in the United States. Lemborexant earned FDA approval on December 20, 2019, as a dual orexin receptor antagonist (DORA) for adults with insomnia, and it is increasingly used in patients who are already on antidepressant regimens.

The result: a clinician sees a patient on trazodone who still has fragmented sleep and considers adding lemborexant. Or a psychiatrist adds trazodone to a patient already stabilized on lemborexant. Either sequence creates a combination that is pharmacologically active on at least two separate axes.

The Scale of the Clinical Problem

A 2022 analysis published in the Journal of Clinical Sleep Medicine estimated that more than 8 million adults in the U.S. Used a prescribed sleep aid alongside an antidepressant in the same calendar year. [1] Trazodone was the most common antidepressant in that overlap group. As DORA use expands, the probability of a prescriber encountering this specific pairing rises each year.

Why Lemborexant Is Different From Older Sleep Agents

Older hypnotics, such as zolpidem and benzodiazepines, act on GABA-A receptors. Lemborexant instead blocks orexin-1 and orexin-2 receptors, suppressing the wake-promoting signal rather than non-selectively depressing the CNS. That mechanism difference does not eliminate sedation overlap with other agents. It does, however, change the pharmacokinetic interaction profile considerably, because lemborexant metabolism is almost entirely CYP3A4-dependent. [2]

Mechanism of Interaction: Two Separate Pathways

The lemborexant, trazodone interaction operates through distinct pharmacodynamic and pharmacokinetic mechanisms. Understanding both is necessary to predict the clinical severity in an individual patient.

Pharmacodynamic Pathway: Additive CNS Depression

Lemborexant suppresses orexinergic arousal signaling. Trazodone produces sedation through antagonism of histamine H1 receptors and serotonin 5-HT2A receptors, as well as alpha-1 adrenergic blockade. These are different receptor systems, but the downstream outcome for both is reduced CNS arousal.

When two agents that each independently reduce CNS arousal are combined, the effect is at minimum additive and may be supra-additive in susceptible individuals. The FDA prescribing information for lemborexant states explicitly: "The risks of next-day psychomotor impairment, including impaired driving, are increased if Dayvigo is taken with other CNS depressants." [2]

Trazodone clearly meets the definition of a CNS depressant. Its histamine and alpha-1 receptor blockade produces sedation that peaks within one to two hours of ingestion and has a half-life of five to nine hours in standard-release formulations. Lemborexant has a median Tmax of one to three hours and a half-life of approximately 17 to 19 hours. The sedative windows overlap substantially through the first half of the night and may extend into morning hours when both drugs are on board.

Pharmacokinetic Pathway: CYP3A4 Substrate Competition

Lemborexant is primarily metabolized by CYP3A4. The FDA label categorizes it as a major CYP3A4 substrate, meaning that agents which inhibit or induce this enzyme will materially change lemborexant plasma exposure. [2]

Trazodone is itself a CYP3A4 substrate and has been characterized in vitro as a weak-to-moderate CYP3A4 inhibitor at higher concentrations. [3] At the doses typically used for insomnia (25 to 100 mg), trazodone's inhibitory effect on CYP3A4 is generally mild. At antidepressant doses (150 to 400 mg), CYP3A4 inhibition becomes more clinically relevant.

The practical consequence: co-administration of trazodone at antidepressant doses may modestly increase lemborexant area under the curve (AUC), prolonging and intensifying its sedative effect beyond what either drug would produce alone.

A useful clinical framework organizes the interaction risk by trazodone dose tier:

Tier 1 (Trazodone 25 to 100 mg for insomnia). CYP3A4 inhibition is minimal. Pharmacodynamic sedation overlap is the dominant concern. Start lemborexant at 5 mg.

Tier 2 (Trazodone 150 to 300 mg for depression). Both pharmacodynamic and pharmacokinetic interactions are clinically relevant. Lemborexant 5 mg is the appropriate starting dose. Monitor for next-morning impairment at each follow-up for at least the first four weeks.

Tier 3 (Trazodone 300 to 400 mg for depression or treatment-resistant insomnia). CYP3A4 inhibition at this dose range warrants the same caution as a moderate CYP3A4 inhibitor. Consider whether lemborexant is the best DORA choice, or whether the patient would be better served by treating the depression more aggressively to resolve the insomnia secondarily.

FDA Label Guidance on Lemborexant and CNS Depressants

The Dayvigo prescribing information approved by FDA provides direct dose guidance for concurrent CNS depressant use.

The Label's Exact Language

The FDA label states: "The use of Dayvigo with other CNS depressants increases the risk of CNS depression. Dose adjustment of Dayvigo and/or the other CNS depressant may be necessary." [2] The label further instructs prescribers to "avoid use of Dayvigo in combination with other CNS depressants when the CNS depressant provides a sufficient sleep benefit on its own."

That second sentence is important for the trazodone question specifically. If a patient is taking trazodone 100 mg and sleeping adequately, adding lemborexant needs a clear clinical rationale beyond convenience.

Absolute Contraindications in the Lemborexant Label

Lemborexant is absolutely contraindicated with strong CYP3A4 inhibitors such as itraconazole, clarithromycin, and ritonavir-containing regimens, because those agents can increase lemborexant AUC by more than 300%. [2] Trazodone does not meet the threshold of a strong CYP3A4 inhibitor, so the absolute contraindication does not apply. The interaction is classified as requiring caution and dose management rather than hard prohibition.

Dose Recommendations from the Label

When used with moderate CYP3A4 inhibitors, the FDA label for lemborexant specifies a maximum dose of 5 mg. [2] Trazodone at antidepressant doses sits in the weak-to-moderate inhibitor category. Applying the label's conservative framework means treating any trazodone dose at or above 150 mg as sufficient reason to cap lemborexant at 5 mg until the patient's tolerance is established.

Trazodone's Pharmacology: Why It Matters Here

Trazodone is approved by the FDA for major depressive disorder. Its use for insomnia is off-label but extremely prevalent, and the pharmacology driving sleep benefit is mechanistically separate from its antidepressant effect. [3]

Receptor Profile

At low doses (25 to 100 mg), trazodone's H1 and 5-HT2A antagonism dominates, producing sedation with relatively little serotonin reuptake inhibition. At doses of 150 mg and above, serotonin transporter inhibition becomes clinically meaningful, adding antidepressant activity but also increasing the theoretical risk of serotonin-related adverse effects when combined with serotonergic agents.

Lemborexant has no serotonergic mechanism. The combination does not carry a serotonin syndrome risk. That is an important distinction when counseling patients who are concerned about their antidepressant regimen.

Half-Life and Next-Morning Carry-Over

Standard trazodone has a half-life of five to nine hours. Extended-release trazodone (Oleptro) has a half-life of approximately 10 hours. Combined with lemborexant's 17-to-19-hour half-life, a patient who takes both drugs at 10 p.m. May still have meaningful plasma concentrations of both compounds at 7 a.m. This is the pharmacokinetic substrate for next-morning psychomotor impairment.

A 2021 study in Sleep Medicine Reviews evaluated residual sedation from orexin receptor antagonists and noted that the risk of morning-after impairment scales with concomitant CNS depressant use, independent of the specific agent's mechanism. [4]

Clinical Evidence on Lemborexant Safety and Efficacy

No published randomized controlled trial has enrolled patients on concurrent trazodone and lemborexant as its primary design. The evidence base for this combination therefore comes from the lemborexant clinical program's subgroup data, drug interaction studies from the FDA submission package, and postmarketing pharmacovigilance.

The SUNRISE-1 and SUNRISE-2 Trials

SUNRISE-1 (N=291) and SUNRISE-2 (N=949) were the key phase 3 trials supporting lemborexant approval. [5,6] Both trials excluded patients on CNS depressants, which is standard for sleep trial design but means they do not directly characterize the interaction risk.

In SUNRISE-2, lemborexant 5 mg reduced subjective sleep onset latency by a mean of 27.1 minutes versus placebo at month 6 (P<0.0001), and lemborexant 10 mg reduced it by 28.9 minutes. [6] These are the efficacy benchmarks against which the added risk of a CNS depressant combination must be weighed.

Drug Interaction Studies in the FDA Submission

The FDA review package for lemborexant included a dedicated CYP3A4 drug interaction study using itraconazole as the index inhibitor. Itraconazole 200 mg/day increased lemborexant AUC by approximately 3.7-fold. [2] No trazodone-specific interaction study was conducted, which is typical for a weak-to-moderate inhibitor in the CNS drug category.

E2006-A001-104: The Dedicated DDI Study

Study E2006-A001-104, referenced in the Dayvigo prescribing information, used midazolam as a CYP3A4 probe to characterize lemborexant's own inhibitory potential. Lemborexant did not meaningfully inhibit CYP3A4 at clinically relevant doses, confirming the interaction is unidirectional: trazodone acts on lemborexant's clearance, not the reverse. [2]

Monitoring Parameters and Clinical Warnings

What to Monitor at Initiation

When starting lemborexant in a patient already on trazodone, or adding trazodone to established lemborexant therapy, the following parameters require active assessment:

Daytime somnolence. Ask specifically at the first follow-up visit (two to four weeks in). Patients often underreport drowsiness unless directly queried.

Driving safety. The FDA label for lemborexant includes a specific warning about next-day driving impairment. Adding trazodone amplifies this risk. Patients should be advised not to drive or operate heavy machinery the morning after first use, and to reassess their subjective alertness before driving on subsequent mornings.

Fall risk. Older adults are disproportionately affected by sedative combinations. A 2020 cohort study published in JAMA Internal Medicine found that DORA use was associated with a fall risk increase of approximately 1.5-fold in adults over 65; co-administration of additional sedatives was not specifically modeled but is expected to increase that estimate. [7]

Complex sleep behaviors. The lemborexant label carries a warning for sleepwalking, sleep driving, and other parasomnias. Trazodone has also been associated with parasomnias in case reports. The combination has not been studied in this context, but the theoretical risk is additive.

Hepatic Impairment

In patients with mild hepatic impairment (Child-Pugh A), lemborexant AUC increases approximately 1.7-fold relative to healthy controls. In moderate hepatic impairment (Child-Pugh B), AUC increases approximately 2.4-fold. The label caps lemborexant at 5 mg in mild hepatic impairment and states avoidance in moderate-to-severe impairment. [2] Trazodone is also hepatically metabolized. A patient with hepatic disease receiving both drugs faces compounded exposure increases from impaired clearance of both agents.

Patient Counseling Points

Translating the pharmacology into language patients can act on is a core prescriber responsibility. The following points cover the most actionable guidance.

Timing of Administration

Both lemborexant and trazodone should be taken within 30 minutes of intended sleep onset, not at dinner. Taking them earlier extends the period of peak sedation overlap with waking hours the next morning.

Alcohol Is Additive to Both Drugs

Alcohol is a CNS depressant that further compounds sedation from both lemborexant and trazodone. The FDA label for lemborexant states that patients should not take it with alcohol. [2] This counseling point is often missed when focus is on the prescription-drug interaction alone.

When to Call the Prescriber

Patients should contact their prescriber if they experience any of the following: difficulty waking in the morning, morning sedation lasting past three hours, episodes of sleepwalking or unusual nighttime behavior, or a fall upon waking.

Do Not Stop Trazodone Abruptly

Patients sometimes decide on their own to stop trazodone when they start a new sleep medication. Abrupt discontinuation of trazodone after prolonged use at antidepressant doses can precipitate withdrawal symptoms including anxiety, agitation, and rebound insomnia. Dose tapering over at least two to four weeks is generally recommended.

Special Populations

Older Adults (65 and Older)

The FDA label for lemborexant does not require dose adjustment on the basis of age alone. However, the 2023 American Geriatrics Society Beers Criteria list all orexin receptor antagonists as potentially inappropriate medications in older adults due to fall and fracture risk, with a recommendation to use with caution. [8] Trazodone is also flagged in the Beers Criteria for orthostatic hypotension and sedation risk. Combining two agents that appear on the Beers list warrants explicit documentation of the risk-benefit discussion in the medical record.

Pregnancy and Breastfeeding

Lemborexant is a Pregnancy Category not yet formally classified under the new FDA labeling rule, but animal studies showed fetal harm at exposures above the maximum recommended human dose. Trazodone carries similar precautions. Neither drug is recommended during pregnancy or breastfeeding. [2,3] Women of childbearing potential should be counseled on contraception.

Patients With Obstructive Sleep Apnea

Lemborexant labeling advises caution in patients with obstructive sleep apnea (OSA). Adding trazodone, which can suppress upper-airway tone, increases this concern. Patients with untreated OSA should generally not receive two sedating agents until the apnea is adequately managed with CPAP or another intervention.

Alternatives to Consider

Some patients may have a clinical reason to avoid the combination entirely. Alternatives worth considering include:

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment per the American College of Physicians and the American Academy of Sleep Medicine, with durable effects that do not carry drug interaction risk. [9]

If a DORA is necessary and trazodone must continue, suvorexant (Belsomra) is the other available DORA and shares a similar CYP3A4-dependent metabolism and CNS depressant warning profile. The interaction class is the same; suvorexant does not represent a pharmacologically safer option in this specific pairing.

If sedation is the goal and antidepressant effect is also needed, mirtazapine at 7.5 to 15 mg has strong evidence for both sleep and depression with a different receptor profile, though it carries its own CNS depressant interaction concerns and metabolic side effects.